By Lisa Kiesel and Hans Hirsch - co.value - A Cytel Brand / Cytel
Published on April 2, 2026 · Updated on June 11, 2026
Lisa Kiesel contributes EVA market access expertise to EU HTA and AMNOG questions. Hans Hirsch leads business development at the JCA and AMNOG interface.
The five theses at a glance
The Delta-Dossier is the national translation of European JCA evidence into the requirements of the German AMNOG process.
The JCA dossier and the AMNOG dossier differ in assessment question, comparison benchmark, methodological requirements and evidence currency.
Five interfaces are decisive for the Delta-Dossier: PICO scoping, appropriate comparator therapy, endpoints, subgroups and evidence updates.
Five factors determine national robustness: assessment question, comparator therapy, patient-relevant endpoints, methodological fit and timing.
| Thesis | Core message | Risk for Germany | Implication for the Delta-Dossier |
|---|---|---|---|
| 1. EU HTA does not replace AMNOG | The national added-benefit assessment remains decisive. | The JCA does not fully answer the German assessment question. | Assess the German research question separately. |
| 2. The Delta-Dossier is translation | General references are not enough. | JCA content does not automatically cover national requirements. | Reference, interpret and supplement at section level. |
| 3. The work starts before submission | PICO scoping and evidence planning become relevant early. | Late comparator and PICO checks create gaps. | Test German relevance before the national dossier starts. |
| 4. The risks sit in comparator therapy and endpoints | Comparators, endpoints and methods determine robustness. | European evidence may not be patient-relevant or fit for Germany. | Secure comparator therapy, endpoints, subgroups and analyses. |
| 5. Timing becomes critical | Evidence updates and JCA publication shape the process. | The national evidence base may diverge from the JCA dossier. | Plan updates, data cuts and timelines early. |
With tovorafenib/OJEMDA, the first practical test of this interface is now available. The G-BA benefit assessment published on 17 August 2026 shows how content from a JCA dossier is reused in a real German AMNOG dossier and where the national assessment applies its own requirements.
What happens after a JCA in the German AMNOG process?
Following a Joint Clinical Assessment, the German early benefit assessment remains a separate national procedure. The JCA dossier and JCA report can be relevant where their content addresses the German assessment question. National requirements for populations, appropriate comparator therapy, patient-relevant endpoints, methods, subgroups and evidence updates nevertheless remain in place.
The Delta-Dossier addresses this interface. It identifies which European content can be used or specifically referenced for Germany and where selection, adaptation, additional analyses or new national content are required.
JCA dossier, JCA report, AMNOG dossier and Delta-Dossier compared
| Item | JCA dossier | JCA report | AMNOG dossier | Delta-Dossier |
|---|---|---|---|---|
| What is it? | Manufacturer evidence submission | Output of the European clinical assessment | German national benefit dossier | Working term for translation and supplementation |
| Level | EU | EU | Germany | EU-to-Germany interface |
| Decision on German added benefit? | No | No | Basis for national assessment | No |
| Separate regulatory template? | Yes | European report format | AMNOG modules | No |
The distinction is also relevant procedurally. For tovorafenib, the JCA dossier was among the documents used in the German benefit assessment. The final JCA report had not yet been published when the German procedure started and could therefore not be considered in the assessment published on 17 August 2026.
The five theses on the Delta-Dossier at a glance
The Delta-Dossier translates European JCA evidence into the requirements of the German AMNOG process. Five interfaces are particularly relevant: the assessment question, PICO and comparator, endpoints and methods, national additions, and evidence updates and timing.
| Thesis | Key point | Risk for Germany | Implication |
|---|---|---|---|
| 1. EU HTA does not replace AMNOG | JCA provides a European clinical assessment, not a German added-benefit decision. | The assessment questions may differ. | Assess the German question separately. |
| 2. Translation, not cross-referencing | References do not replace a completeness check. | JCA content may not cover German requirements. | Reference, select, adapt and supplement. |
| 3. Work starts before submission | PICO scoping and evidence planning determine applicability. | German populations or comparators may be considered too late. | Include German scenarios early. |
| 4. Risks lie in comparators and endpoints | Comparator, patient relevance and methods determine usability. | European evidence may not be usable nationally. | Check Modules 3 and 4 early. |
| 5. Timing becomes critical | JCA and national evidence may be available at different times. | New data or a later report may change the starting point. | Prepare timing scenarios. |
Thesis 1: EU HTA does not replace the national assessment in Germany
The Joint Clinical Assessment does not replace the German early benefit assessment. The European assessment provides clinical evidence against the European assessment scope, while the national assessment of added benefit remains part of AMNOG.
Tovorafenib confirms this distinction. Because the medicine has orphan-drug status, its medical added benefit is considered proven by virtue of marketing authorisation in Germany; the G-BA procedure assesses its extent. The JCA, by contrast, addressed relative clinical effectiveness and safety across eight PICO questions.
Thesis 2: The Delta-Dossier is a translation task
References to the JCA dossier can make national dossier development more efficient, but they do not replace an assessment of whether the content meets German requirements. Specific references are possible; broad or dynamic references are not sufficient. The national AMNOG modules remain in place and there is no separate regulatory Delta-Dossier template.
The work consists of four tasks: reuse suitable content, selection of relevant PICOs and results, adaptation of content or analyses, and addition of Germany-specific content, updates or analyses.
The first practical test shows that Module 3 remains strongly national: epidemiology, the German statutory health insurance target population, healthcare context and costs require Germany-specific preparation. Module 4 offers greater scope for reuse, including study characteristics, methodology, operationalisation and results.
Thesis 3: The real work starts long before the Delta-Dossier
National applicability is determined to a considerable extent before the Delta-Dossier is written. PICO scoping, comparator strategy, study design and evidence planning determine which European questions can later be answered with robust evidence.
The tovorafenib assessment scope covered three populations and eight PICO questions. No usable comparative results were available for six of the eight questions. The case also shows why individualised treatment comparators, external evidence and indirect comparisons need to be considered early. An evidence gap that exists at JCA stage cannot be solved by the later dossier structure alone.
Thesis 4: The greatest risks lie in comparators, endpoints and methods
Whether European evidence is suitable for Germany depends particularly on the comparator, patient relevance of endpoints and methodological usability. A European comparator and the appropriate comparator therapy specified by the G-BA do not necessarily coincide.
For PICO 5, the JCA presented an unanchored Matching-Adjusted Indirect Comparison between tovorafenib and dabrafenib plus trametinib. The JCA described substantial uncertainty, including possible residual confounding and small effective sample sizes. The G-BA did not use the MAIC for the German assessment.
PFS and objective response were included in the European scope but were not considered suitable patient-relevant efficacy endpoints in the submitted operationalisations. Reuse does not replace national quality assessment: population, endpoint, operationalisation, analysis population and statistical method must still be assessed against German requirements.
Thesis 5: Timing and evidence updates become critical success factors
JCA and AMNOG may operate with different evidence bases and publication timelines. The Delta-Dossier therefore needs to account for evidence updates and the availability of the final JCA report.
The JCA used the two-year FIREFLY-1 data cut, while the German dossier included a newer three-year data cut. The G-BA used the three-year cut of 6 June 2025 because it provided the longest follow-up. The national evidence base therefore need not be identical to the JCA evidence base.
Preparation should answer three questions: What evidence cut-off underpins the JCA dossier? What new evidence will be available before the German procedure starts? When will the final JCA report be available relative to AMNOG?
From the JCA to the G-BA resolution
| Phase | Relevance for the Delta-Dossier |
|---|---|
| JCA scoping and PICOs | Assess German relevance of populations, comparators and outcomes early. |
| JCA dossier | Structure evidence and analyses with national applicability in mind. |
| Marketing authorisation and AMNOG preparation | Update evidence and complete national requirements. |
| AMNOG dossier | Specifically reference, select, adapt and supplement JCA content. |
| Benefit assessment and hearing | Address evidence against national standards and remaining uncertainty. |
| G-BA resolution | National decision on added benefit or its extent. |
The first practical test confirms the five interfaces
Tovorafenib is a single orphan-drug procedure and not a blueprint for all future Delta-Dossiers. It nevertheless provides observations across all five theses: separate national assessment, selective evidence transfer, early evidence gaps, national methodological review, and different evidence and publication timelines.
FAQ on the Delta-Dossier under EU HTA
Does the JCA replace the AMNOG dossier?
No. The Joint Clinical Assessment can provide evidence for the national process, but it replaces neither the AMNOG dossier nor the German assessment of added benefit.
What is a Delta-Dossier?
The Delta-Dossier describes the additional content and evidence needed between the European JCA dossier and the German AMNOG dossier so that European evidence can be used robustly at national level.
When does Delta-Dossier preparation start?
Preparation starts before the national dossier is compiled, especially during PICO scoping, evidence planning, comparator scenarios, endpoint selection and timing decisions.
Why is the appropriate comparator therapy critical?
The appropriate comparator therapy defines the relevant comparison benchmark in the AMNOG process. If the JCA evidence does not reflect that benchmark, references to the JCA dossier are not sufficient.
What role do evidence updates play?
Evidence updates matter because literature searches, data cuts and newly available studies must still be current when the AMNOG process starts. As a result, the national evidence base can differ from the JCA dossier.